Abstract:Objective To verify the efficacy and safety of the highly selective α1A-adrenoceptor antagonist silodosin in the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia.Methods A randomized,double-blind,placebo-controlled,multi-center study was performed.Patients with benign prostatic hyperplasia who met the inclusion/exclusion criteria were randomly assigned to silodosin (8 mg/day) group or placebo group (2:1).A total of 501 subjects were enrolled and included in the Full Analysis Set (FAS),338 in silodosin group and 163 in placebo group.479 subjects were included in the Per-Protocol (PP) Set,325 in silodosin group and 154 in placebo group.The treatment duration was 12 weeks.The primary endpoint was IPSS change from baseline at Week 12.The secondary endpoints were QOL score before and after the treatment,maximun flow rate (Qmax),average urinary flow rate (Qave),and the change in residual urine volume.At baseline,IPSS were 20.87 ± 5.03 in silodosin group and 20.99 ±4.80 in placebo group.Meanwhile in both group,QOL score were 4.95 ± 0.67 and 4.99 ± 0.69 ; Qmax were (10.82±2.73) ml/s and (10.31 ±2.74) ml/s; Qave were (5.70 ±2.11) ml/s and (5.48± 1.86)ml/s ; residual urine volume were (20.17 ± 23.72) ml and (18.45 ± 19.66) ml.The evaluation also included change of total IPSS in the early stage of drug administration (i.e.Week 1 or 2).Adverse events during the course of treatment were closely and recorded for safety evaluation.Results The change of IPSS from baseline at Week 12 was-7.17 ±6.44 for silodosin vs-5.77 ±5.95 for placebo (P ＜0.05).In early stage of drug administration,there were statistically significant differences between silodosin and placebo group in terms of IPSS changes from baseline at Week 1 (-2.29 ± 3.53 vs-1.25 ± 2.95,P ＜ 0.05)and Week2 (-3.42±4.43 vs-2.01 ±3.77,P＜0.05),respectively.The change of QOL score before and after treatment was-1.74 ± 1.37 for silodosin vs-1.40 ± 1.31 for placebo (P ＜ 0.05).123 adverse events occurred in silodosin group with the occurrence rate of 35.86％,including ejaculation failure,dry mouth,dizziness and bradycardia,and 39 adverse events occurred in placebo group with the occurrence rate of 23.21％,including dizziness,skin rash,bradycardia,and dry mouth.Conclusions Silodosin is a fast acting medication,which can significantly improve self-reported symptoms in patients with benign prostatic hyperplasia and enhance their quality of life.Silodosin is effective and safe in the treatment of voiding disorders caused by benign prostatic hyperplasia.

Effects of silodosin on bladder activity in rats with frequent urination induced by pelvic venous congestion

Effects of silodosin and tadalafil on bladder dysfunction in spontaneously hypertensive rats: Possible role of bladder blood flow

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review

Silodosin: An Update on Efficacy, Safety and Clinical Indications in Urology

Effect of the Duration of Bladder Overdistention on Renal Function and Morphology in Rats.

The role of Silodosin as a new medical expulsive therapy for ureteral stones: a meta-analysis

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Clinical Trial to Investigate Silodosin in the Treatment of Benign Prostatic Hyperplasia

Effect of Alpha-Blocker on Distal Ureteric Calculi: A Comparative Study

Silodosin and its potential for treating premature ejaculation: a preliminary report

Serotonin (5-HT) 2A/2C Receptor Agonist (2,5-Dimethoxy-4-idophenyl)-2-aminopropane Hydrochloride (DOI) Improves Voiding Efficiency in the Diabetic Rat

Silodosin as a medical expulsive therapy for distal ureteral stones: A systematic review and meta-analysis

Effects of alpha-1-adrenergic receptor subtype-selective antagonists on lower urinary tract function in rats with bladder outlet obstruction

Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms

Clinical application of highly selectiveα1A-AR antagonist silodosin in benign prostatic hyperplasia

Efficacy and safety of silodosin, vardenafil versus silodosin in combination with vardenafil as a medical expulsive therapy for distal ureteric stones: a prospective randomized double-blind study

Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia

Silodosin versus naftopidil in the treatment of premature ejaculation: A prospective multicenter trial

Effect of α1D-adrenoceptor blocker for the reduction of ureteral contractions

The effect of the 5-HT2A/2C receptor agonist DOI on micturition in rats with chronic spinal cord injury.

A COMPARATIVE STUDY OF EFFICACY OF SILODOSIN AND TAMSULOSIN INPATIENT OF URETERIC CALCULI

Two-year follow up of silodosin on lower urinary tract functions and symptoms in patients with benign prostatic hyperplasia based on prostate size: a prospective investigation using urodynamics